![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 28, 2010 9:23:12 AM
NDYN
Naerodynamics
The BRIEF version of what you should know about NDYN
The Float is less than 6 million!
The chart is in breakout mode (check it out below)
The company is Actual and has a profitable Service
It is on High News Watch
It is on High News Watch
It is on High News Watch
It is on High News Watch
The 6 million float and chart makes this a great play all by itself…Add potential news with an already reputable company on top of that and we are facing some blue skies.
A bit more DD for those of you that want to truly understand the actual potential
What NDYN does is contract Telephone Companies to allow NaeroDynamics come in and run their software, which maximizes the contracted company’s potential AND saves them about 10% of their operating costs.
NDYN provides continuous performance improvement, financial management and business information solutions for telecommunications companies as well as large corporate enterprises that utilize significant telecommunications networks.
NDYN has the capability to cleanse and normalize large quantities of data. Its unique ECM (Enterprise Circuit Manager) proprietary software has been specifically developed to carry out end to end circuit inventory management quickly and accurately from the disparate data sets obtained from clients. This software, along with the vast hands-on experience and know-how of the NDYN team, provides an intellectual advantage that equates to the identification of significant savings, typically 15 % - 20%, (but the management team has attained as much as 40% in previous engagements), of a customers’ annual network expenditure.
For example,last year NDYN saved one Telco 180 million dollars and a second Telco 900 million. Some huge names have been contracted and the more companies that realize the simple, guaranteed, money saving services that NDYN can provide, the quicker NDYN will grow and prosper.
Look at the big names NDYN has already contracted:
PAETEC Communications . PAETEC is the 2nd largest CLEC in the U.S. with an off-net spend of approximately $860MM.
Vialtus. Vialtus is a small UK carrier backed by a large private equity firm that is currently executing an acquisition/ roll-up strategy of other European based telecom oriented companies.
TelePacific Corp. Telepacific Corp. is the 5th largest CLEC in the country and the largest CLEC in California and Nevada.
Telwares. Telewares is one of the largest telecom consulting firm in the U.S. with over $1Billion in revenue and over 2000 customers.
Some HUGE names are in there. That means more potential money for NDYN to save clients, and more money for them to make themselves! The process is tried and true, and now NDYN is truly getting the exposure it deserves as a company and as a stock!
The Company has an extremely strong pipeline of additional potential Telecom carriers and large corporate enterprises. Some industry statistics:
1. The total spent by corporate enterprises on Telecommunications services in 2006 was $148 Billion per annum (source Gartner Insight)
2. North America and Western Europe will account for around 70% of the total based on market share statistics for similar markets (e.g. IT spend)
3. This gives a target market of $ 103 Billion annually. NDYN’s target market is the top 20% of companies that account for 80% of the expenditure.
4. The opportunity target cost base is $80 Billion per annum
Recent COEP News
- Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering • PR Newswire (US) • 06/20/2024 12:47:00 PM
- Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting • PR Newswire (US) • 05/30/2024 12:47:00 PM
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 • PR Newswire (US) • 10/31/2023 01:01:00 PM
- Coeptis Therapeutics Announces $2 Million Private Placement • PR Newswire (US) • 10/24/2023 12:30:00 PM
- Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology • PR Newswire (US) • 10/11/2023 11:30:00 AM
- Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 01:15:00 PM
- Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting • PR Newswire (US) • 10/04/2023 11:30:00 AM
- Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa • PR Newswire (US) • 09/27/2023 11:30:00 AM
- Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection • PR Newswire (US) • 09/14/2023 11:30:00 AM
- Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment • PR Newswire (US) • 09/11/2023 11:30:00 AM
- Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer • PR Newswire (US) • 08/30/2023 05:00:00 PM
- Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics • PR Newswire (US) • 08/17/2023 11:30:00 AM
- Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic • PR Newswire (US) • 08/01/2023 12:00:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM